Takeda Pharmaceutical Company Limited American Depositary Shares (each
TAK Real Time Price USDRecent trades of TAK by members of U.S. Congress
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes in TAK holdings by institutional investors
Quarterly net insider trading by TAK's directors and management
* Insider trading data parsed from SEC Form 4 filings by Quiver Quantitative. Sign up for the Quiver API for real-time access.
- 1M
- 3M
- 6M
- YTD
- 1Y
- 2Y
- 5Y
- MAX
About
Key Metrics
Return (1d)
Return (30d)
Return (1Y)
CAGR (Total)
Max Drawdown
Beta
Alpha
Sharpe Ratio
Win Rate
Average Win
Average Loss
Annual Volatility
Annual Std Dev
Information Ratio
Treynor Ratio
Total Trades
Metrics Definitions
Disclaimer: The performance results shown are based on historical backtesting and are hypothetical in nature. Backtested performance does not represent actual trading and does not account for all market factors that may affect execution, such as liquidity, slippage, and changing market conditions. Past performance is not necessarily indicative of future results. There is no guarantee that any trading strategy will be profitable or avoid losses.
-
Alpha
Measures a portfolio's risk-adjusted performance against that of its benchmark
Learn More -
Annual Standard Deviation
Measures how much the portfolio's total return varies from its mean or average.
Learn More -
Annual Volatility
A statistical measure of the dispersion of returns for the portfolio.
Learn More -
Average Win
The average return (%) for trades that resulted in a positive return.
-
Average Loss
The average return (%) for trades that resulted in a negative return.
-
Beta
A measure of the volatility of the portfolio compared to the market as a whole.
Learn More -
CAGR
CAGR (Compounded Annual Growth Rate), is the historical annualized rate of return for an investment strategy, throughout the backtest period.
Learn More -
Information Ratio
A measurement of portfolio returns beyond the returns of its benchmark compared to the volatility of those returns.
Learn More -
Max Drawdown
the maximum observed loss from a peak to a trough of a portfolio, before a new peak is attained.
Learn More -
Sharpe Ratio
The Sharpe Ratio is a measure of historical risk-adjusted return, which quantifies the amount of return that an investor received per unit of risk.
Learn More -
Total Trades
The total number of trades made by this strategy.
-
Treynor Ratio
Attempts to measure how successful an investment is in providing compensation to investors for taking on investment risk.
Learn More -
Win Rate
The percentage of total trades that resulted in a positive return.
Be the first to see our newest insights and key updates across all datasets.
Government lobbying spending instances
-
$1,370,000 Oct 20, 2025 Issue: Budget/Appropriations Medicare/Medicaid Health Issues Taxation/Internal Revenue Code Trade (domestic/foreign) Defense
-
$1,570,000 Aug 26, 2025 Issue: Budget/Appropriations Medicare/Medicaid Health Issues Taxation/Internal Revenue Code Trade (domestic/foreign) Defense
-
$490,000 Apr 22, 2025 Issue: Budget/Appropriations Taxation/Internal Revenue Code Trade (domestic/foreign) Defense Medicare/Medicaid Health Issues
-
$390,000 Apr 18, 2025 Issue: Budget/Appropriations Medicare/Medicaid Health Issues Taxation/Internal Revenue Code Trade (domestic/foreign) Defense
-
$970,000 Oct 18, 2024 Issue: Budget/Appropriations Defense Trade (domestic/foreign) Taxation/Internal Revenue Code Health Issues Medicare/Medicaid
-
$1,050,000 Jul 22, 2024 Issue: Defense Trade (domestic/foreign) Taxation/Internal Revenue Code Health Issues Medicare/Medicaid
-
$460,000 Apr 22, 2024 Issue: Defense Budget/Appropriations Trade (domestic/foreign) Taxation/Internal Revenue Code Health Issues Medicare/Medicaid
-
$510,000 Jan 19, 2024 Issue: Budget/Appropriations Trade (domestic/foreign) Taxation/Internal Revenue Code Health Issues Medicare/Medicaid
-
$1,380,000 Oct 20, 2023 Issue: Budget/Appropriations Trade (domestic/foreign) Taxation/Internal Revenue Code Health Issues Medicare/Medicaid
TAK Estimated quarterly lobbying spending
TAK Revenue by Segment or Geography
New TAK patent grants
-
Patent Title: Heterocyclic compound Mar. 21, 2017
-
Patent Title: 1-arylcarbonyl-4-oxy-piperidine compounds useful for the treatment of neurodegenerative diseases Mar. 07, 2017
-
Patent Title: Radiolabeled compounds and their use as radiotracers for quantitative imaging of phosphodiesterase (pde10a) in mammals Feb. 28, 2017
-
Patent Title: Heterocyclic compound Feb. 21, 2017
-
Patent Title: Dihydroxy aromatic heterocyclic compound Feb. 07, 2017
-
Patent Title: Tricyclic compound Jan. 31, 2017
-
Patent Title: 4-oxo-3,4-dihydro-1,2,3-benzotriazine modulators of gpr139 Jan. 31, 2017
-
Patent Title: Pyridazinone compounds as phosphodiesterase inhibitors and methods of treating disorders Jan. 24, 2017
-
Patent Title: Cyclic compounds Jan. 03, 2017
-
Patent Title: Substituted pyrido[2,3-b]pyrazines as phosphodiesterase 2a inhibitors Dec. 27, 2016
-
Patent Title: Sulfonamide derivative and use thereof Dec. 27, 2016
-
Patent Title: Nitrogen-containing heterocyclic compound Dec. 13, 2016
-
Patent Title: Method for producing microcapsule powder Dec. 13, 2016
-
Patent Title: Crystal of fused heterocyclic compound Dec. 06, 2016
-
Patent Title: Aromatic ring compound Nov. 29, 2016
-
Patent Title: Heterocyclic compound and use thereof Nov. 22, 2016
-
Patent Title: Nitrogen-containing heterocyclic compound Nov. 22, 2016
-
Patent Title: Heterocyclic compound and use thereof Nov. 15, 2016
-
Patent Title: Cyclopentylbenzamide derivatives and their use for the treatment of psychotic and cognitive disorders Nov. 15, 2016
-
Patent Title: Quinoxaline derivatives as gpr6 modulators Nov. 08, 2016
-
Patent Title: Cyclopropanamine compound and use thereof Nov. 08, 2016
-
Patent Title: Heterocyclic compound Nov. 08, 2016
-
Patent Title: Method for producing sulfonyl chloride compound Nov. 08, 2016
-
Patent Title: Orally disintegrating solid preparation Nov. 08, 2016
-
Patent Title: Solid preparation Nov. 08, 2016
-
Patent Title: Substituted 2- amidoquinazol-4-ones as matrix metalloproteinase-13 inhibitors Oct. 25, 2016
-
Patent Title: Substituted-1,4-dihydropyrazolo[4,3-b]indoles Oct. 25, 2016
-
Patent Title: Sulfonyl piperidine derivatives and their use for treating prokineticin mediated diseases Oct. 25, 2016
-
Patent Title: Nitrogenated heterocyclic compound Oct. 18, 2016
-
Patent Title: Compounds Oct. 11, 2016
-
Patent Title: Substituted pyrazolo[1,5-a] pyrimidines as calcium receptor modulating agents Sep. 20, 2016
-
Patent Title: 1-arylcarbonyl-4-oxy-piperidine compounds useful for the treatment of neurodegenerative diseases Sep. 13, 2016
-
Patent Title: Aromatic ring compound Sep. 13, 2016
-
Patent Title: Indazole derivatives Sep. 06, 2016
-
Patent Title: Dry coated tablet Sep. 06, 2016
-
Patent Title: Heterocyclic compound Aug. 30, 2016
-
Patent Title: Coated preparation Aug. 30, 2016
-
Patent Title: Apoptosis signal-regulating kinase 1 inhibitors Aug. 02, 2016
-
Patent Title: Heterocyclic compound and use therefor Aug. 02, 2016
-
Patent Title: Pyridinyl and fused pyridinyl triazolone derivatives Aug. 02, 2016
-
Patent Title: Heterocyclic compound Jul. 12, 2016
-
Patent Title: Methods of treating hypertension with at least one angiotensin ii receptor blocker and chlorthalidone Jul. 12, 2016
-
Patent Title: Aromatic ring compound Jul. 05, 2016
-
Patent Title: Heterocyclic compound Jun. 21, 2016
-
Patent Title: Cinnoline derivatives Jun. 14, 2016
-
Patent Title: Benzimidazole derivatives as mch receptor antagonists Jun. 14, 2016
-
Patent Title: Heterocyclic compound Jun. 14, 2016
-
Patent Title: Process for producing solid particles Jun. 14, 2016
-
Patent Title: Tetrahydronaphthyridine somatostatin receptor 5 antagonists May. 31, 2016
-
Patent Title: Thienopyrimidine compounds and use thereof May. 24, 2016
Federal grants, loans, and purchases
Estimated quarterly amount awarded to TAK from public contracts
Recent insights relating to TAK
Recent picks made for TAK stock on CNBC
ETFs with the largest estimated holdings in TAK
- ... Highest Price Target
- ... Median Price Target
- ... Lowest Price Target
|
Analyst
|
Firm
|
Current
|
Previous
|
Date
|
|---|
- Is $TAK stock a Buy, Sell, or Hold?
- What is the price target for $TAK stock?
* Analyst consensus is not financial advice. Please see our data disclaimers .
|
Shareholder
|
Shares Held
|
|---|
- Who owns $TAK stock?
- Who owns the most shares of $TAK stock?
- What funds own $TAK stock?
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view TAK Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.6 trillion in fiscal 2024. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with over 50% derived from the US, 20% from Japan, 20% from Europe and Canada.